Comprehensive Biotech Summary
Introduction to Biotechnology
Biotechnology is a multidisciplinary science that applies biological concepts to engineering and
technology, modifying living organisms, cells, and biomolecules for the benefit of humans, agriculture,
and the environment. Historically, biotechnology began with artificial crop breeding and animal cross-
breeding. Modern biotechnology relies on DNA recombination technology, enabling precise genome
modification with minimal failure.
DNA Recombination Technology (Genetic Engineering):
Involves in-vivo artificial modification of an organism’s genome by adding foreign DNA.
Generates Recombinant DNA (rDNA): DNA artificially created by combining genetic material from
different sources, sometimes across species.
Enables production of gene products and gene clones.
Target gene is called Gene of Interest (GOI).
Gene Cloning:
Purpose: Amplification of GOI for therapeutic, research, or industrial applications.
Methods: DNA Recombination or Polymerase Chain Reaction (PCR).
Plasmids and Vectors
Plasmids:
Small, circular, double-stranded DNA molecules independent of chromosomal DNA.
Common in bacteria, used as vectors to deliver GOI.
Contain origin of replication (ORI), antibiotic resistance genes, and restriction enzyme sites.
Vectors:
DNA molecules used to deliver GOI into host cells.
Types: Plasmids, bacteriophages, Yeast Artificial Chromosomes (YACs), Cosmids.
Requirements: ORI, selectable markers (e.g., antibiotic resistance), restriction sites.
Note: All plasmids may serve as vectors, but not all vectors are plasmids.
Host Cells (Expression Systems):
Page 1 of 5
Host organisms produce the gene product of GOI.
Transformation introduces rDNA into host cells, which then replicate and express the gene.
Key Enzymes in Recombinant DNA Technology
1. Restriction Endonucleases (Molecular Scissors):
Recognize specific palindromic DNA sequences (4–8 bp) and cleave phosphodiester bonds.
Types: Sticky ends (overhangs) or Blunt ends (no overhang).
Examples: EcoRI, HindIII, XhoI.
Enable precise insertion of GOI into vectors.
2. DNA Ligase (Molecular Glue):
Catalyzes phosphodiester bond formation between adjacent nucleotides.
Joins vector and GOI to form stable rDNA.
Also functions in DNA replication and repair (joins Okazaki fragments).
DNA Recombination Process
1. Identification and Isolation of GOI:
Use of Probes (short, labeled ssDNA or RNA fragments) to detect target sequence.
Restriction enzymes cleave GOI and vector to produce compatible ends.
2. Ligation:
DNA ligase joins vector and GOI to form rDNA.
3. Introduction into Host (Transformation):
Host treated (e.g., CaCl₂) to enhance permeability.
rDNA enters host; transformed cells replicate, expressing GOI.
4. Selection and Identification:
Markers (antibiotic resistance, colorimetric changes) identify transformed clones.
5. Expression and Protein Production:
rDNA transcribed and translated; proteins isolated and purified for therapeutic/industrial
use (e.g., insulin).
Probes
Short, single-stranded nucleic acid fragments (100–1000 bp), complementary to target DNA/RNA.
Labeled with detectable tags: radioactive, fluorescent, enzymatic.
Page 2 of 5
Applications: molecular diagnostics, pathogen detection, genetic mapping, forensic analysis,
gene expression studies.
Highly sensitive, useful in detecting viral (HPV, HIV, Hepatitis B/C), protozoal, and helminth
infections.
Polymerase Chain Reaction (PCR)
Amplifies DNA sequences millions of times in vitro.
Requires template DNA, primers, dNTPs, and Taq polymerase.
Thermocycler cycles:
1. Denaturation (94°C): dsDNA separates into ssDNA.
2. Primer Annealing: Forward and reverse primers bind to target strands.
3. Extension (72°C): Taq polymerase synthesizes new DNA strands.
Uses: detection of pathogens, forensic DNA profiling, paternity testing, gene cloning.
Human Genome Project (HGP)
Initiated 1990, led by US NIH; completed 2003.
Human genome: ~20,000–25,000 genes, 3.2 billion nucleotides across 23 chromosome pairs.
Tandem repeats: short DNA repeats unique to individuals.
Immunology in Biotechnology
Epitope: Specific region on an antigen recognized by an antibody.
Paratope: Antigen-binding site on antibody; complementary to epitope.
Epi-Paratope Interaction: Lock-and-key, non-covalent, reversible; ensures specificity.
B-Cell Activation and Monoclonal Antibodies (mAbs):
Naive B-cells produce unique BCRs (paratopes).
Antigen binding activates B-cells, leading to clonal expansion (plasma and memory cells).
mAbs: Identical antibodies from a single B-cell clone, specific to one epitope.
Polyclonal Antibodies (pAbs):
Mixture from multiple B-cell clones; recognize multiple epitopes on same antigen.
Hybridoma Technology (mAb Production):
Page 3 of 5
1. Immunization of mouse with antigen.
2. Isolation of B-cells from spleen.
3. Fusion with immortal myeloma cells → hybridomas.
4. Screening for desired antibody.
5. Cloning for continuous antibody production.
Uses: Cancer detection (tumor markers), infectious disease diagnostics (TB, Syphilis, Lyme), imaging
(PET scans).
Gene Therapy
Corrects genetic defects by replacing, repairing, silencing, or adding genes.
Delivery: In-vivo (direct) or Ex-vivo (harvested cells modified and transplanted).
Carriers: Viral (adenoviruses, retroviruses, herpes simplex) or non-viral (liposomes,
electroporation, gene gun).
Mechanism:
1. Identify defective gene.
2. Clone functional GOI and select vector.
3. Engineer vector and package GOI.
4. Deliver vector in-vivo or ex-vivo.
5. Express gene to restore protein function.
Applications:
Hemophilia: Adenoviral vector delivers clotting factor gene to liver.
Adrenoleukodystrophy (ALD): Ex-vivo lentiviral gene therapy on HSCs to restore ABCD1 function.
Other disorders: Sickle cell anemia, Huntington’s, muscular dystrophy, cystic fibrosis.
Cystic Fibrosis (CF):
CFTR gene mutation → defective Cl⁻ transport → thick mucus → respiratory, digestive,
reproductive complications.
Therapy: Viral vector delivery or aerosolized liposome-CFTR gene; no approved treatments yet.
Stem Cell Therapy
Uses stem cells to restore/regenerate tissues.
Sources: Bone marrow, adipose tissue, umbilical cord, embryonic.
Targets: Neurodegenerative disorders, spinal injuries, diabetic neuropathy.
Page 4 of 5
Potential: Improve patient health and quality of life.
Biotech in Vaccines
Vaccines contain non-pathogenic antigens to induce immune response.
Biotech methods:
1. Use monoclonal antibodies for antigen identification.
2. Synthesize non-pathogenic antigens using cloned genes.
3. Synthesize foreign peptides as vaccines.
Examples:
Hep-B: rDNA in yeast to produce surface antigen.
HPV: Gene inserted into insect cells, protein purified.
Influenza: Annual strain-specific vaccines.
COVID-19: mRNA vaccines (Pfizer, Moderna, J&J) encoding viral spike protein, inducing immunity.
Malaria: Weakened parasite (Sanaria) under development.
Rabies: Initially from purified horse serum antibodies.
Biotech Products for Disease Treatment
1. Recombinant Proteins: Treat diabetes, GH deficiency, anemia.
2. Monoclonal Antibodies: Target cancer cells, pathogens, autoimmune diseases.
3. Vaccines: Prevent viral diseases (Hep-B, HPV, Influenza, Rabies, Polio).
Key Takeaways
Biotechnology integrates molecular biology, genetics, and engineering for therapeutic,
diagnostic, and industrial applications.
Techniques such as DNA recombination, PCR, and hybridoma technology are central to biotech
innovations.
Gene therapy and stem cell therapy represent the frontier of personalized medicine.
Vaccines, recombinant proteins, and monoclonal antibodies demonstrate tangible clinical
applications of biotechnology.
Page 5 of 5